Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus anlotinib and penpulimab for advanced relapsed metastatic solid tumors
ChiCTR2300071296Phase 2Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in Nonhematologic neoplasms, sponsored by Shanxi Bethune Hospital. Primary endpoint: Objective response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2300071296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071296.